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Abstract: The transient receptor potential ankyrin 1 (TRPA1), a member of the TRP superfamily
of channels, acts as ‘polymodal cellular sensor’ on primary sensory neurons where it mediates
the peripheral and central processing of pain, itch, and thermal sensation. However, the TRPA1
expression extends far beyond the sensory nerves. In recent years, much attention has been paid to
its expression and function in non-neuronal cell types including skin cells, such as keratinocytes,
melanocytes, mast cells, dendritic cells, and endothelial cells. TRPA1 seems critically involved in
a series of physiological skin functions, including formation and maintenance of physico-chemical
skin barriers, skin cells, and tissue growth and differentiation. TRPA1 appears to be implicated in
mechanistic processes in various immunological inflammatory diseases and cancers of the skin, such
as atopic and allergic contact dermatitis, psoriasis, bullous pemphigoid, cutaneous T-cell lymphoma,
and melanoma. Here, we report recent findings on the implication of TRPA1 in skin physiology
and pathophysiology. The potential use of TRPA1 antagonists in the treatment of inflammatory and
immunological skin disorders will be also addressed.
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1. Introduction
Transient receptor potential (TRP) channels are polymodal cation channels primarily
permeable to calcium, which work as cellular sensors implicated in many physiological
functions, ranging from pure sensory activities, such as nociception and temperature sensa-
tion, and homeostatic functions, such as osmoregulation, to many other functions, such as
muscle contraction and vasomotor control [1]. In mammals, the superfamily of TRP chan-
nels encompasses 28 members [1], behaving as non-selective cation permeable channels,
and classified into six subfamilies: The canonical or classic (TRPC1-7), vanilloid (TRPV1-6),
melastatin (TRPM1-8), long TRP ankyrin (a solitary member is the transmembrane pro-
tein 1 [TRPA1]), and the more distant relatives, polycystins (TRPP1-5) and mucolipins
(TRPML1-3) [1–3]. TRPs are expressed in a wide variety of both excitable and non-excitable
cells [4–10]. Most TRPs have been localized to the plasma membrane where they non-
selectively allow the influx of extracellular cations [11]. However, their presence has been
documented in cellular organelles, with a pivotal role in establishing/maintaining vesicular
calcium homeostasis and in regulating membrane trafficking [12]. TRPs are considered
unique polymodal cell sensors, as their gating is directly operated by a plethora of ex-
ogenous and endogenous physical stimuli and chemical mediators or by changes in the
intracellular environment [13]. As several TRPs localized in a subset of primary sensory
neurons, they result as highly implicated in sensing physiological and noxious agents
and more generally in nociceptive stimuli perception in a variety of tissues and organs,
including the skin [14,15].
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Emerging evidence suggests that multiple TRPs are involved in the regulation of
the cutaneous functions. Apart from their prominent expression and role in nociceptive
neurons, where they mediate the peripheral and central processing of pain, itch, and ther-
mal sensation [16–20], some TRPs are found in non-neuronal cells [4,5,7] including skin
cells [6,21–23], where they are critically involved in formation and maintenance of physico-
chemical skin barriers, skin cells, and organ growth and differentiation, and cutaneous
immunological and inflammatory processes. This review focuses on the functional role
of TRPA1 in various cutaneous functions both under physiological and pathophysiologi-
cal conditions.
2. TRPA1 in Skin Physiology
2.1. Cutaneous Nerve Fibers and Neurogenic Inflammation
The skin-localized sensory afferents are involved in the neuronal processing of mul-
tiple sensory modalities. Aβ-fibers with thickly myelinated axons, thus fast conduction
velocities and low activation thresholds, are the predominant class of fibers responsible for
sensing light touch. A subpopulation of C-fibers is responsible for gentle touch and light
forces similar to Aβ-fibers [24–26]. Similar low-threshold Aδ-fiber responses have been
observed in humans, but it remains to be determined if these fibers also influence touch
perception [27]. The perception of acute noxious or painful touch are typically derived from
the activation of high-threshold unmyelinated C-fibers and thinly myelinated Aδ-fibers.
A specific subset of C-fiber and Aδ- fiber nociceptors is exclusively sensitive to the
selective TRPV1 agonist, capsaicin, the pungent ingredient in hot chili peppers, and thereby
defined as ‘capsaicin-sensitive’ sensory neurons. TRPV1-expressing neurons comprise
a subgroup of neurons defined as peptidergic because of their ability to produce neu-
ropeptides, including the calcitonin gene-related peptide (CGRP) and tachykinins, such as
substance P (SP) and neurokinin A (NKA) [28,29], which upon peripheral release, cause
inflammatory responses, collectively referred to as “neurogenic inflammation” [28,29].
TRPA1 is present in 30–50% of TRPV1-expressing neurons and rarely exists in neurons
which do not express TRPV1 [30].
The most prominent feature of the TRPA1 resides in its unique sensitivity for several
exogenous and endogenous agonists which, based on their structure, activate the channel
covalently, or modulate its activity in a different way. A number of naturally occurring
TRPA1 agonists mainly found in alimentary sources include herbs and spices, such as
cinnamaldehyde, contained in the cinnamon oil extracted from the Cinnamomum [31],
several isothiocyanate compounds, such as allyl or benzyl isothiocyanate contained in mus-
tard oil or wasabi, obtained from the Brassica seeds [32], and allicin and diallyl disulfide,
contained in garlic (Allium sativum) [33]. Other rather heterogenous substances qualified
as TRPA1 channel stimulants include volatile irritants, such as acrolein and crotonalde-
hyde [34,35], chemicals of industrial origin, [36–38], general anesthetics (e.g., isoflurane [39],
lidocaine [40], propofol [41]), and laboratory chemicals (e.g., formalin [42–44]). Additional
aldehydes which stimulate TRPA1 are formaldehyde [45], acetaldehyde [46] and croton-
aldehyde [35,47] (all contained in cigarette smoke). These compounds, share a reactive
chemical structure which enables them to covalently modify specific cysteine residues
located within the cytoplasmic N-terminal region of the protein [48], resulting in TRPA1
activation. These features justify the large use of these compounds to better understand
the mechanism of action and the role of the channel.
Non-reactive compounds which are unable to modify the channel covalently include
compounds from plant origin, such as menthol [49], thymol, and carvacrol [50,51]. The
non-electrophilic component contained in Cannabis sativa, delta-9-tetrahydrocannabinol
(THC), also activates the TRPA1 channel without producing any covalent modification [52].
Different medicines or their metabolites such as clotrimazole [53], nifedipine [54], and
non-steroidal anti-inflammatory drugs, such as diclofenac [55] and acyl-glucuronide ibupro-
fen [56], represent an additional subgroup of exogenous TRPA1 activators.
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The last ten years have witnessed a series of discoveries that have placed the TRPA1
channel as a major sensor of oxidative, nitrative, and carbonylic stress for the peripheral
nervous system. Reactive oxygen (ROS), nitrative (RNS), and carbonylic (RCS) species
have shown the ability to gate TRPA1 on peripheral terminals primary sensory neurons,
thereby signaling pain, and neurogenic inflammation. ROS activate TRPA1 through a
cysteine oxidation or disulfide formation [57], whereas RNS activate the channel through a
S-nitrosylation reaction [57].
Among ROS, TRPA1 activators comprise hydrogen peroxide (H2O2) [37,39,58],
hypochlorite (OCl-), superoxide (O2-) [38]. Among RNS, NO [39,59,60], and peroxyni-
trite [39] are TRPA1 agonists. Metabolites generated by peroxidation or nitrosylation of
plasma membrane phospholipids, including 4-hydroxynonenal (4-HNE), 4-hydroxyhexenal
(4-HHE), 4-oxo-2-nonenal (4-ONE), and nitrooleic acid (9-OA-NO2) activate TRPA1 chan-
nels [37,48,61–63]. During inflammation cyclooxygenase induction and activation result in
the release of proinflammatory and proalgesic prostaglandings and isoprostanes, which
via a non-enzymatic dehydration generate cyclopentenone prostaglandin and isoprostane
including 15-deoxy-∆12,14-PGJ2 (15-d-PGJ2), PGA2 and PGA1, and 8-isoprostane-PGA2
are formed. Cyclopentenone PGs and iso-PGs have been recognized as TRPA1 activa-
tors [64,65]. Finally, among the endogenously produced mediators, the malodourous gas
hydrogen sulfide (H2S), produced by cysteine metabolism and endowed with vasodilata-
tory and other properties [66], has also been identified as a TRPA1 stimulant [67].
2.2. Keratinocytes Differentiation, Proliferation and Barrier Function
Growing evidence has revealed that TRPs are actively involved in the regulation of
skin physiology [68–77]. TRPV1 expression has been identified in epidermal and hair
follicle keratinocytes, dermal mast cells, sebaceous gland-derived sebocytes, and den-
dritic cells [78,79], which suggest functional roles in homeostatic and ‘sensory’ functions
not limited to cutaneous nerve fibers. TRPV2 has been found in keratinocytes [80] and
macrophages [81], and TRPV3 in blood vessels [7] and keratinocytes [82]. The presence
of TRPV4 has been reported in basal and suprabasal keratinocytes of healthy human
skin [22,73]. Finally, TRPA1 has been found in keratinocytes, melanocytes, and fibrob-
lasts [6,23] (Figure 1).
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In human skin, immunoreactivity for the TRPA1 channel has been detected in both
keratinocytes and melanocytes [6]. It was also observed that the treatment of keratinocytes
with icilin, a selective TRPA1 agonist, increased the expression of genes involved in cellular
adhesion and extracellular matrix protein synthesis [6].
The production of the stratum corneum is one of the main roles of epidermal ker-
atinocytes. Some studies showed that the administration of TRPA1 activators as well as
the application of cold stimuli to the skin of mice, in which the epidermal barrier was
mechanically disrupted, accelerated the rate of barrier regeneration [83]. Conversely, the
application of a TRPA1 antagonist prevented the beneficial effects and markedly delayed
the barrier healing [83]. Moreover, cold-induced TRPA1 activation resulted in a specific
increase in intracellular calcium in human cultured epidermal keratinocytes, much higher
than that observed in dorsal root ganglion cells [84], thus revealing that epidermis might
be more sensitive to low temperature than the peripheral nervous system, and TRPA1
expressed in keratinocytes may have a central role in thermo-sensation of the skin [85].
Despite at low levels, TRPA1 mRNA was recently detected in mouse keratinocytes, where
its selective deletion caused a marked deficit in mechanically-evoked ATP release, high-
lighting a possible involvement of keratinocytes in mechano-transduction [86]. Collectively,
these findings suggest a “constitutively active” role for TRPA1 in the epidermal barrier
homeostasis. TRPA1 is activated by ultraviolet radiation (UVR) in melanocytes, where
its activation by UVR non-detrimental doses results in an early melanin synthesis [23].
However, additional TRPs may contribute to the formation and maintenance of the skin
barrier [87], participate in the differentiation and growth of the skin cells [88], and ensure
immunological properties during inflammatory processes [88], as TRPV4 activation has
been involved in cell survival mechanisms after skin exposure to noxious heat.
3. TRPA1 in Skin Diseases
3.1. Atopic Dermatitis and Allergic Contact Dermatitis
Atopic dermatitis (AD) and allergic contact dermatitis (ACD) are common inflamma-
tory skin diseases characterized by skin barrier disruption and an inflammatory response
dominated by T helper 2 (Th2) cells and related products, such as interleukin (IL)-4, IL-5,
and IL-13 [89,90]. Pruritus, which is characteristically histamine-independent, represents
the most troublesome symptom of both diseases, resulting in a significantly impaired
patient’s quality of life.
TRPA1 contributes to the pathogenesis of chronic [91] and acute histamine-independent
pruritus, such as those evoked in mice by injection of chloroquine [92] and the proenkephalin
product, BAM8-22 [92–94]. In either human or murine AD models, TRPA1 has been shown
to be significantly over-expressed by several cell types, including keratinocytes, mast cells,
and dermal sensory nerve afferents [91]. TRPA1 expression was also enhanced in cell
bodies of dorsal root ganglion (DRG) neurons from AD-mice [91]. In comparison, animal
models of ACD revealed an over-expression of TRPA1 only on DRG neuronal cells, while
no increased channel expression has been observed in non-neuronal skin cells [95].
A TRPA1-dependent pathway of itch in AD has been firstly identified by using a
murine model of the disease induced by IL-13 [91]. In this study, IL-13 caused a chronic
AD disease in mice characterized by an intensive chronic itch and increased expression
of TRPA1 in mast cells, dermal sensory nerve fibers, and cell bodies of DRG neurons.
Interestingly, mast cells recruited by IL-13 and localized in close proximity with TRPA1+
dermal afferents promoted a TRPA1-mediated local secretion of neuropeptides. In addition,
pharmacological TRPA1 blockade selectively attenuated the itch-evoked scratching. Ge-
netic deletion of mast cells in these mice led to significant reduction in the itch-scratching
behaviors and lowered the TRPA1 expression in dermal neuropeptide containing afferent
fibers [91]. Altogether, these data reveal a complex interaction among TRPA1+ dermal af-
ferent nerves and TRPA1+ mast cells in the Th2-mediated inflammatory milieu underlying
chronic itch in AD [91] (Figure 1).
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An additional study revealed that in a different murine model of AD induced by
2,4-dinitrochlorobenzene (DNCB), genetic deletion of TRPA1 attenuated pathological find-
ings of AD, including ear thickness, epidermal hyperplasia and pruritus, and dermal
infiltration by mast cells, Th2 cytokines, and macrophages [96]. Moreover, DNCB, capable
of inducing ACD in exposed humans, has been shown to directly and dose-dependently
activate TRPA1 [97]. Likewise, in a murine model of ACD induced by topical application
of oxazolone [95], TRPA1 deficiency correlated with milder ACD symptoms including pru-
ritus, and lower levels of inflammatory cytokines and T-cell activation. More intriguingly,
oxazolone has been shown to directly activate TRPA1, resulting in enhanced release of me-
diators of neurogenic inflammation and pruritus, including 5-hydroxytryptamine (5-HT),
SP, and NKA. In addition, the absence of TRPA1 reduced the number of SP-responsive
neurons, which are involved in the central transmission of pain and itch sensations. Simi-
lar results were obtained using a mouse model of ACD induced by urushiol, the poison
ivy allergen [95]. Recently, in an oxazolone-induced murine model of ACD, the topical
application of tacrolimus induced a persistent up-regulation of TRPA1 in DRG neurons
and contributed to development of itch, thus explaining the pruritus and stinging sensa-
tion produced by the drug in humans [98]. Induction of skin dryness in mice has been
associated with TRPA1 activation, that also correlated with changes in the gene expression
profile driving to skin hyperplasia and lichenification [99].
In chronic allergic itch, multiple pathways of TRPA1 activation have been shown.
These include a keratinocyte-neuron axis based on the release of thymic stromal lym-
phopoietin [100] and periostin [101], two AD-associated cytokines directly released by
keratinocytes, and a Th2-cell-neuronal pathway based on the release of the pruritogenic
cytokine IL-31 [102]. Although these studies suggest a role of TRPA and many channel
ligands have been studied, yet TRPA1 blockers remain to be used clinically as anti-itch
drugs. Off-target effects are a risk for TRPA1 ligands, given TRPA1 broad expression
in different neuronal and non-neuronal cellular districts, which encompasses different
biological functions. For this reason, the development of such drugs should proceed with
caution. Nevertheless, since evidence showed that the TRPA1 is crucially involved in the
pathogenesis of AD and ACD, the pharmacological inhibition of the channel could be
a valuable complementary strategy for local control of skin inflammation and pruritus
observed in both diseases.
3.2. Psoriasis
Psoriasis is a common chronic inflammatory skin disease, characterized by erythema,
skin thickness, and scaling [103]. Pruritus is observed in 60-90% of the patients [104].
Emerging evidence has highlighted a contribution of nociceptive sensory nerve endings in
the pathogenesis of psoriasis, with a multi-faced role in detecting noxious stimuli, promot-
ing the activation of immune cells and modulating the immune microenvironment [105].
Of note, different studies showed increased C-fiber innervation in the epidermis of pso-
riatic skin lesions [106–110]. The altered quantity of nerve fibers was associated with the
increased expression of neuropeptides including SP and CGRP in psoriasis epidermal
tissue [108,111]. Elevated neuropeptide content in the plasma of patients with psoriasis
also correlated with psoriasis severity index scores [112]. Moreover, cutaneous dener-
vation induces a reduction of skin inflammation in psoriasis patients and in mice with
psoriasiform dermatitis [113].
More recently, the role of TRPA1 in psoriasis has been explored. It was originally
reported that in a murine model of imiquimod (IMQ)-induced psoriasis-like lesions, topical
application of the drug was associated with elevated expression of TRPA1 in affected skin
areas [114]. Similar results were obtained in psoriatic skin from human subjects where
TRPA1 and TRPV1 genes were over-expressed [115]. Mechanistic studies provided contrast-
ing results on the role of TRPA1 in murine models of psoriasis. Pharmacological blockade
or genetic deletion of TRPA1 could, in fact, worsen psoriasis dermatitis and nocifensive
and itch behavior in mice, thus suggesting a protective role for TRPA1 in psoriasis [116].
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At the molecular level, the pathology in TRPA1 deleted mice was characterized by higher
levels of inflammatory cytokines, including IL-1β, TNF-α, and IL-22 compared to wild-type
mice [116]. The protective role for TRPA1 in psoriasis was strengthened by the observation
that a 3-weeks treatment with dry food containing mustard seed (5%) reduced IMQ in-
flammation in mice [117]. Conversely, another study reported that TRPA1 genetic deletion
sustained the dermal inflammation and the Th17-related cytokines expression in a severe
model of IMQ-induced psoriasis, which also induced a systemic inflammatory reaction
in mice [114]. As TRPA1 is expressed by primary sensory neurons, keratinocytes, and im-
mune cells, we can speculate that channel function is affected by the immune environment.
Collectively, these data suggested that TRPA1 activation or inhibition may simultaneously
act in a protective manner in psoriasis, arguably by regulation of the activity of TRPV1
(Figure 1).
3.3. Cutaneous T-Cell Lymphoma
Cutaneous T-cell lymphomas (CTCL) are a heterogeneous group of primary cutaneous
lympho-proliferative disorders, including mycosis fungoides (MF) and Sézary syndrome
(SS) as the most common clinical presentations [118]. Pruritus is a debilitating symptom
in patients with MF and SS [118]. In these patients, the shift to Th2-type immunity, with
neoplastic cells producing enhanced Th2-associated cytokines, including IL-4 and IL-31,
partly explains the severity of pruritus [119,120]. However, a recent study reported TRPA1
as a critical mediator involved in CTCL-associated itch [121]. Recent data showed that miR-
711, released by neoplastic skin-resident T-cells, induced TRPA1-dependent itch in mice by
direct TRPA1 activation [121]. Interestingly, the itching activity of miR-711 was mediated by
a short and evolutionary conserved core sequence that was both necessary and sufficient for
the TRPA1 gating. In addition, in contrast with conventional TRPA1 agonists, miR-711 did
not homogeneously elicit pain, itch, and neurogenic inflammation [121]. Such diversity was
ascribed to a different binding domain in the extracellular portion of the protein, a shorter
opening time of TRPA1, and the ensuing lower calcium permeability or the activation
of different nerve terminals afferents, which encode diverse sensory modalities. Finally,
inhibition of miR-711 activity with an extracellular complementary sequence or disruption
of the miR-711/TRPA1 interaction with a blocking peptide significantly attenuated the
scratching behavior in a mouse model of CTCL. Collectively, these data revealed an
unconventional role of extracellular miRNAs as itch mediators and TRPA1 modulators
and confirmed the biological relevance of this interaction in the pathophysiology of CTCL-
associated itch.
3.4. Other Pruritic Skin or Systemic Diseases
Chronic histamine-independent pruritus occurs in a wide variety of other cutaneous
and systemic diseases. A common skin disease characterized by pruritus is scabies, a
contagious parasitic infestation caused by the mite Sarcoptes scabiei hominis [122]. In the
skin of patients with scabies, non-histaminergic itching receptors, including TRPA1, TRPV1,
and the protease-activated receptor 2 (PAR2), have been found to be over-expressed [123].
Interestingly, increased PAR2 expression was associated with increased tryptase+ cells and
reduced histamine+ cells near the dermal-epidermal junction, potentially suggesting a
TRPA1/mast cell pathway similar to that previously reported in AD [123] (Figure 1).
A common systemic cause of itch is that related to liver dysfunction, which in turn
causes an elevation of circulating bile acids (BA). Remarkably, one study reported the co-
expression of the G-protein-coupled BA receptor 1 (TGR5) and TRPA1 in cutaneous afferent
neurons in mice [124]. TRG5 activation by BA sensitized TRPA1 via enhanced intracellular
signaling through Gβγ, protein kinase C, and calcium in vitro. In mice over-expressing
TRG5, the exacerbated spontaneous scratching behavior was reduced by TRPA1 antago-
nists, thus supporting a coactivation of TGR5 and TRPA1 in BA induced pruritus [124].
A study reported TRPA1 over-expression in the epidermis of patients with bullous
pemphigoid, a rare autoantibody-mediated blistering disease characterized by intense
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pruritus, compared to healthy skin, but channel expression did not significantly correlate,
neither with eosinophil dermal infiltration nor with the severity of pruritus [125] (Figure 1).
Finally, a distinctive cause of pruritus induced by physical factors is that following
burn injuries. Recently, one study revealed that mRNA levels of TRPA1 as well as TRPV4
were increased in the skin of itching burn scars [126]. However, further studies are needed
to identify the role of TRPA1 in burn-associated itch.
4. Therapeutic Perspectives and Future Directions
The hypothesis that TRPA1 is implicated in chronic neuropathic [9,10,127–129], in-
flammatory [129,130], migraine [131,132], and cancer pain [133] is robustly supported. In
contrast, current understanding of the pathophysiological roles of TRPA1 in the skin needs
further investigations.
Here we showed that TRPA1 may exert a number of functions in different physiologi-
cal and pathological skin processes. Increasing evidence indicates a major role of TRPA1 in
histamine-independent itch occurring in chronic inflammatory skin diseases such as AD,
liver dysfunction, or neoplastic diseases, such as cutaneous T-cell lymphoma, thus making
these conditions suitable areas of investigation for drugs that target TRPA1. Among the
various TRPA1 antagonists that have shown selectivity toward TRPA1, only five have
been tested in clinical trials for the treatment of pain or other conditions (e.g., allergic
asthma) [134–138].
A recent review identified 28 patent applications for TRPA1 antagonists from 2015
to 2019. Among them, some have been successfully tested in pre-clinical models of skin
diseases such atopic dermatitis [139]. In contrast, none have entered large clinical trials
for the treatment of skin diseases in humans. A thorough review of registered clinical
trials (www.clinicaltrial.gov) using the key words “TRPA1 and skin” or “TRPA1 and
pruritus” finds only one study on the effects of L-menthol, a substance that does not
directly target TRPA1, as a topical counter-irritant on cutaneous pain and hyperalgesia
provoked by topical application of the TRPA1-agonist trans-cinnamaldehyde in healthy
human volunteers. Despite robust evidence of TRPA1 involvement in pruritic skin diseases,
reasons explaining the delay in translating TRPA1 antagonists from the pre-clinical to the
clinical setting, remain unclear. However, other therapeutic strategies are worth exploring.
It is noteworthy that multiple molecules can selectively activate TRPA1 inducing
long-lasting desensitization of the channel. Crotalphine has been shown to inhibit a chem-
ically induced inflammatory hypersensitivity in mice via the desensitization of TRPA1-
peptidergic nerve endings [140]. In allergic rhinitis, a disease sharing some pathological
features with AD and ACD, a combination of azelastine hydrochloride and fluticasone pro-
pionate has been shown to induce desensitization of TRPA1 and TRPV1 expressing sensory
neurons, thus ameliorating local airway inflammation [141]. Finally, after the exposure to
isopetasin, extracts from the butterbur plant (Petasites hybridus), and parthenolide, a major
constituent of Tanacetum parthenium, TRPA1 channel and the TRPA1 expressing neurons
undergo to a dose-dependent neuronal desensitization which may account for the relief of
pain and neurogenic inflammation of the two plant extracts [142,143].
TRPA1 remains a field of active investigation for other skin conditions. For example,
TRPA1 proteins have been found in melanoma cell lines [144–146], but the role of TRPA1 in
melanoma in vivo remains far less clear. TRPA1 is of paramount importance to signal pain
associated with skin cancers or related therapies, including dacarbazine-induced pain in
melanoma [147], or pain associated with photodynamic therapy used for the treatment of
non-melanoma skin cancer [148]. Likewise, it may be intriguing to explore TRPA1 activity
in pain associated with inflammatory or autoimmune skin diseases, such as pemphigus
vulgaris [149].
Finally, increasing evidence supports a role for TRPA1 in fibrosis associated with
systemic diseases [150,151]. Accordingly, the possibility that TRPA1 promotes fibrosis in
fibrogenic skin diseases (e.g., scleroderma) or wound healing is worth investigating, due to
the lack of effective therapeutic strategies in such conditions.
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